In a multicenter Italian study of 104 adult patients with severe bacterial lower respiratory tract infections, the safety and efficacy of a regimen of high dose, once- daily tobramycin alone or in combination with antipseudomonas betalactams was assessed. The overall bacteriological response was an elimination of the original pathogen in 70% of the patients while the overall clinical response mirrored the bacteriological results with a successful clinical outcome in 78% of patients. Adverse experiences were, in general, few and mild without oto- or nephrotoxicity. The once-daily, high dose regimen of tobramycin proved to be a safe and efficacious therapy for severe lower respiratory tract infections in adult patients. © 1995 E.I.F.T. srl - Firenze.

Once-daily tobramycin therapy in lower respiratory tract infections

Crimi, N.;
1995

Abstract

In a multicenter Italian study of 104 adult patients with severe bacterial lower respiratory tract infections, the safety and efficacy of a regimen of high dose, once- daily tobramycin alone or in combination with antipseudomonas betalactams was assessed. The overall bacteriological response was an elimination of the original pathogen in 70% of the patients while the overall clinical response mirrored the bacteriological results with a successful clinical outcome in 78% of patients. Adverse experiences were, in general, few and mild without oto- or nephrotoxicity. The once-daily, high dose regimen of tobramycin proved to be a safe and efficacious therapy for severe lower respiratory tract infections in adult patients. © 1995 E.I.F.T. srl - Firenze.
Aminoglycosides; Drug dosing; Lower respiratory tract infection; Tobramycin; Toxicity; Adult; Aged; Anti-Bacterial Agents; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intramuscular; Injections, Intravenous; Italy; Lactams; Lung Diseases; Male; Middle Aged; Tobramycin; Treatment Outcome; Medicine (all); Oncology; Pharmacology; Pharmacology (medical); Infectious Diseases
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/319678
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact